Inga Mandac Rogulj

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer, Hartmut Döhner, Hervé Dombret et al. · International Journal of Molecular Sciences · 2017 · 51 citations · Full text

Medicine, Hematology, Pharmacology +12

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder et al. · Journal of Hematology & Oncology · 2016 · 41 citations · Full text

Medicine, Hematology, Pharmacology +16

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

Théo de Witte, Luca Malcovati, Pierre Fenaux et al. · Haematologica · 2020 · 33 citations · Full text

Medicine, Hematology, Hematologic Oncology +14

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Marlijn Hoeks, Timothy Bagguley, Corine van Marrewijk et al. · Leukemia · 2020 · 28 citations · Full text

Medicine, Hematology, Iron Metabolism Disorders +14

Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Yair Herishanu, Adir Shaulov, Riva Fineman et al. · American Journal of Hematology · 2020 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +11